Cargando…

Rhomboids and regulation of receptor tyrosine kinase ligands shedding

Detalles Bibliográficos
Autores principales:	Karachaliou, Niki, Rosell, Rafael
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Elsevier 2018
Materias:	Commentary
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6284349/ https://www.ncbi.nlm.nih.gov/pubmed/30297146 http://dx.doi.org/10.1016/j.ebiom.2018.09.053

Ejemplares similares

Gene Expression Signatures Predicting Survival and Chemotherapy Benefit in Patients with Resected Non-small-Cell Lung Cancer
por: Rosell, Rafael, et al.
Publicado: (2018)

Evaluation of Biomarkers for HER3-targeted Therapies in Cancer
por: Karachaliou, Niki, et al.
Publicado: (2015)

Co-mutations in EGFR driven non-small cell lung cancer
por: Rosell, Rafael, et al.
Publicado: (2019)

Disulfide isomerase family-6 mediates cisplatin resistance by interfering with apoptosis and autophagy
por: Rosell, Rafael, et al.
Publicado: (2019)

Regulation of Energy Metabolism by Receptor Tyrosine Kinase Ligands
por: Zhao, Meng, et al.
Publicado: (2020)

Deciphering Crosstalk Circuits in Non-small Cell Lung Cancers with an Increasing Interval Length of Low Dose CT Screening
por: Rosell, Rafael, et al.
Publicado: (2015)

Science and biology drives the immune system to cure lung cancer patients: a revolution but not without challenges
por: Karachaliou, Niki, et al.
Publicado: (2018)

Systemic treatment in EGFR-ALK NSCLC patients: second line therapy and beyond
por: Karachaliou, Niki, et al.
Publicado: (2014)

Targeted treatment of mutated EGFR-expressing non-small-cell lung cancer: focus on erlotinib with companion diagnostics
por: Karachaliou, Niki, et al.
Publicado: (2014)

Role of Receptor Tyrosine Kinases and Their Ligands in Glioblastoma
por: Carrasco-García, Estefanía, et al.
Publicado: (2014)

Ligand bias in receptor tyrosine kinase signaling
por: Karl, Kelly, et al.
Publicado: (2021)

Progranulin and the receptor tyrosine kinase EphA2, partners in crime?
por: Chitramuthu, Babykumari, et al.
Publicado: (2016)

Tyrosine kinase signalling in breast cancer
por: Hynes, Nancy E
Publicado: (2000)

PPARγ ligands increase antileukemic activity of second- and third-generation tyrosine kinase inhibitors in chronic myeloid leukemia cells
por: Glodkowska-Mrowka, E, et al.
Publicado: (2016)

Aurora kinases shed light on resistance to EGFR inhibition in head and neck cancer
por: Kim, Donghwa, et al.
Publicado: (2021)

Species-Specific Interactions of Src Family Tyrosine Kinases Regulate Chlamydia Intracellular Growth and Trafficking
por: Elwell, Cherilyn A., et al.
Publicado: (2011)

Emerging Role of Tyrosine Kinases as Drugable Targets in Cancer
por: Na, Il-Kang, et al.
Publicado: (2015)

Current Management of Chronic Myeloid Leukemia with Tyrosine Kinase Inhibitors
por: Haznedaroğlu, İbrahim C.
Publicado: (2013)

Shedding of TRAP by a Rhomboid Protease from the Malaria Sporozoite Surface Is Essential for Gliding Motility and Sporozoite Infectivity
por: Ejigiri, Ijeoma, et al.
Publicado: (2012)

Prospects for the future of epidermal growth factor receptor-tyrosine kinase inhibitors in combination with bevacizumab
por: Chikaishi, Yasuhiro, et al.
Publicado: (2020)

PD-L1 expression associated with better response to EGFR tyrosine kinase inhibitors
por: Rosell, Rafael, et al.
Publicado: (2015)

Combination of immunotherapy with targeted therapies in advanced non-small cell lung cancer (NSCLC)
por: Moya-Horno, Irene, et al.
Publicado: (2018)

A novel ligand-receptor relationship between families of ribonucleases and receptor tyrosine kinases
por: Wang, Ying-Nai, et al.
Publicado: (2018)

Shedding Light on Adaptation
por: Hurley, James B.
Publicado: (2002)

Shedding Light On Cones
por: Knox, Barry E., et al.
Publicado: (2006)

Tyrosine Kinase Ligand-Receptor Pair Prediction by Using Support Vector Machine
por: Yarimizu, Masayuki, et al.
Publicado: (2015)

The neuronal tyrosine kinase receptor ligand ALKAL2 mediates persistent pain
por: Defaye, Manon, et al.
Publicado: (2022)

Rhomboid glossitis caused by candida?
por: Ramli, Inssaf, et al.
Publicado: (2016)

Mechanisms of resistance to osimertinib
por: Lazzari, Chiara, et al.
Publicado: (2020)

Brucella abortus Encodes an Active Rhomboid Protease: Proteome Response after Rhomboid Gene Deletion
por: Marchesini, María Inés, et al.
Publicado: (2022)

Triple Tendon Transfer of the Levator Scapulae, Rhomboid Major, and Rhomboid Minor to Reconstruct the Paralyzed Trapezius
por: Hoang, Victor, et al.
Publicado: (2022)

The dosing of ibrutinib and related Bruton’s tyrosine kinase inhibitors: eliminating the use of brute force
por: Ratain, Mark J., et al.
Publicado: (2022)

The opening dynamics of the lateral gate regulates the activity of rhomboid proteases
por: Bohg, Claudia, et al.
Publicado: (2023)

Profile of alectinib for the treatment of ALK-positive non-small cell lung cancer (NSCLC): patient selection and perspectives
por: Karachaliou, Niki, et al.
Publicado: (2019)

EGFR first- and second-generation TKIs—there is still place for them in EGFR-mutant NSCLC patients
por: Karachaliou, Niki, et al.
Publicado: (2019)

To bind or not to bind – how to down-regulate target genes by liganded thyroid hormone receptor?
por: Weitzel, Joachim M
Publicado: (2008)

The worm sheds light on anesthetic mechanisms
por: Singaram, Vinod K., et al.
Publicado: (2012)

Plasmonics sheds light on the nanotechnology of daguerreotypes
por: Halas, Naomi J.
Publicado: (2019)

cfDNA testing for monitoring response to EGFR tyrosine kinase inhibitors: Time for clinical implementation?
por: Normanno, Nicola, et al.
Publicado: (2020)

Genomic instability as a major mechanism for acquired resistance to EGFR tyrosine kinase inhibitors in cancer
por: Liu, Bing, et al.
Publicado: (2021)

Cannot write session to /tmp/vufind_sessions/sess_u5eg3kjirnqqap93rp3ppt3f1c